Anixa Biosciences (ANIX) Intangibles (2014 - 2020)

Anixa Biosciences' (ANIX) quarterly Intangibles came in at $168000.0 in Q4 2020, up 301.19% on a QoQ basis from $41875.0 in Q2 2019.

Anixa Biosciences (ANIX) Intangibles (2014 - 2020) Analysis & Trends

Anixa Biosciences (ANIX) has 7 years of Intangibles data on file, last reported at $168000.0 in Q4 2020.

Quarterly Intangibles changed N/A year-over-year to $168000.0 in Q4 2020, while the trailing twelve-month figure through Oct 2020 was $168000.0 (changed N/A YoY) and the FY2020 annual result came in at $168000.0, changed N/A from the prior year.
Intangibles rose to $168000.0 in Q4 2020, from $41875.0 in the prior quarter.
In the past five years, Intangibles ranged from a high of $2.3 million in Q1 2016 to a low of $41875.0 in Q2 2019.
A 5-year average of $1.5 million and a median of $1.7 million in 2017 frame the typical range for Intangibles.
Annual changes were most pronounced in 2016 — Intangibles dropped 12.32% — and 2019, when it slumped 97.35%.
Tracing ANIX's Intangibles over 5 years: stood at $2.1 million in 2016, then retreated by 15.71% to $1.7 million in 2017, then tumbled by 52.03% to $837500.0 in 2018, then tumbled by 95.0% to $41875.0 in 2019, then soared by 301.19% to $168000.0 in 2020.
The last three Intangibles figures came in at $168000.0 (Q4 2020), $41875.0 (Q2 2019), and $168000.0 (Q1 2019), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Intangibles (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	412.80 Mn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.31 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	266.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	60.96 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	93.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-
10	Anixa Biosciences	121.44 Mn	121.44 Mn	-	-

Download Data